Depomed settles with generics over Gralise dispute
Depomed, a California-based pharmaceutical company, has settled litigation with two of three companies that sought to launch generic versions of its Gralise (gabapentin) product before patents covering it expire.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
21 August 2014 The US District Court for the District of New Jersey has ruled that Actavis may not launch a generic version of California-based Depomed’s Gralise (gabapentin), it has been announced.
21 August 2014 The US District Court for the District of New Jersey has ruled that Actavis may not launch a generic version of California-based Depomed’s Gralise (gabapentin), it has been announced.
21 August 2014 The US District Court for the District of New Jersey has ruled that Actavis may not launch a generic version of California-based Depomed’s Gralise (gabapentin), it has been announced.